Guilin Sanjin Pharmaceutical Co (002275) Fair Value & Analysis
Healthcare · CN · Market cap 7.3B CNY
Analysis
Guilin Sanjin Pharmaceutical Co (002275) currently trades at ¥12.30, while our model-based Fair Value estimate is ¥16.22 — implying the stock looks roughly 31.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache capsule, compound panax notoginseng stomach pain tablets, Sanqi xueshangning capsules, Sanqi xueshangning powder, compound luo han guo qing fei granules, compound luo han guo lung clearing syrup, compound red root tablets, Shuanghu zhongtongning, liver and kidney tonic granules, and jade leaf detoxification granules. Its products are used in various therapeutic areas, such as urinary system disease, oral and throat, cardiovascular and cerebrovascular disease, neurological diseases, respiratory disease, digestive system disease, internal medicine, musculoskeletal system diseases, and tonic dr…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.